MRNA-3704 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
246メチルマロン酸血症2

246. メチルマロン酸血症


臨床試験数 : 19 薬物数 : 26 - (DrugBank : 3) / 標的遺伝子数 : 17 - 標的パスウェイ数 : 23
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-001061-32-GB
(EUCTR)
25/10/201930/05/2019A clinical study to evaluate mRNA-3704 in Patients with MMAA Global, Phase 1/2, Open Label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3704 in Patients with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]Product Name: mRNA-3704
INN or Proposed INN: NA
Other descriptive name: NA
ModernaTX, Inc.NULLNot RecruitingFemale: yes
Male: yes
34Phase 1;Phase 2United States;United Kingdom
2NCT03810690
(ClinicalTrials.gov)
May 28, 201914/1/2019Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic AcidemiaA Global, Phase 1/2, Open Label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase DeficiencyMethylmalonic Acidemia (MMA);Metabolism, Inborn ErrorsBiological: mRNA-3704ModernaTX, Inc.NULLWithdrawn1 YearN/AAll0Phase 1/Phase 2United States